Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription‐mediated amplification assay in blood donors from Catalonia (Spain)

Medientyp: E-Artikel
Titel: Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription‐mediated amplification assay in blood donors from Catalonia (Spain)
Beteiligte: Sauleda, Sílvia; Ong, Edgar; Bes, Marta; Janssen, Alanna; Cory, Robin; Babizki, Maria; Shin, Tim; Lindquist, Andre; Hoang, Anh; Vang, Lee; Piron, Maria; Casamitjana, Natàlia; Koppelman, Marco; Danzig, Lisa; Linnen, Jeffrey M.
Erschienen: Wiley, 2015
Erschienen in: Transfusion
Sprache: Englisch
DOI: 10.1111/trf.12929
ISSN: 0041-1132; 1537-2995
Entstehung:
Anmerkungen:
Beschreibung: <jats:sec><jats:title>Background</jats:title><jats:p>Hepatitis <jats:styled-content style="fixed-case">E</jats:styled-content> virus (<jats:styled-content style="fixed-case">HEV</jats:styled-content>) is an emerging threat to the safety of blood transfusion. The aim of this study was to determine <jats:styled-content style="fixed-case">HEV</jats:styled-content> immunoglobulin (<jats:styled-content style="fixed-case">Ig</jats:styled-content>)<jats:styled-content style="fixed-case">G</jats:styled-content> and <jats:styled-content style="fixed-case">RNA</jats:styled-content> prevalence in <jats:styled-content style="fixed-case">C</jats:styled-content>atalan blood donors.</jats:p></jats:sec><jats:sec><jats:title>Study Design and Methods</jats:title><jats:p>Nearly 10,000 samples were collected from anonymized, unpaid donors at the <jats:styled-content style="fixed-case">B</jats:styled-content>anc de <jats:styled-content style="fixed-case">S</jats:styled-content>ang i <jats:styled-content style="fixed-case">T</jats:styled-content>eixits (<jats:styled-content style="fixed-case">B</jats:styled-content>arcelona, <jats:styled-content style="fixed-case">S</jats:styled-content>pain) from <jats:styled-content style="fixed-case">J</jats:styled-content>une to <jats:styled-content style="fixed-case">D</jats:styled-content>ecember 2013. For the serology study, a subset of 1082 donations was tested in parallel for <jats:styled-content style="fixed-case">HEV IgG</jats:styled-content> using <jats:styled-content style="fixed-case">W</jats:styled-content>antai and <jats:styled-content style="fixed-case">M</jats:styled-content>ikrogen enzyme‐linked immunosorbent assay tests. Samples were tested individually (individual‐donation nucleic acid test [<jats:styled-content style="fixed-case">ID</jats:styled-content>‐<jats:styled-content style="fixed-case">NAT</jats:styled-content>]) for <jats:styled-content style="fixed-case">HEV RNA</jats:styled-content> using the <jats:styled-content style="fixed-case">P</jats:styled-content>rocleix <jats:styled-content style="fixed-case">HEV</jats:styled-content> assay (95% limit of detection 7.9 <jats:styled-content style="fixed-case">IU</jats:styled-content>/<jats:styled-content style="fixed-case">mL</jats:styled-content>). Procleix repeat‐reactive donations were confirmed by an in‐house real‐time polymerase chain reaction (<jats:styled-content style="fixed-case">PCR</jats:styled-content>) test.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The prevalences of <jats:styled-content style="fixed-case">IgG</jats:styled-content> anti‐<jats:styled-content style="fixed-case">HEV</jats:styled-content> in <jats:styled-content style="fixed-case">C</jats:styled-content>atalan blood donors were 19.96% (<jats:styled-content style="fixed-case">W</jats:styled-content>antai assay) and 10.72% (<jats:styled-content style="fixed-case">M</jats:styled-content>ikrogen assay). Screening of 9998 samples with the <jats:styled-content style="fixed-case">P</jats:styled-content>rocleix <jats:styled-content style="fixed-case">HEV</jats:styled-content> assay yielded three real‐time <jats:styled-content style="fixed-case">PCR</jats:styled-content>‐confirmed and <jats:styled-content style="fixed-case">IgM</jats:styled-content> and <jats:styled-content style="fixed-case">IgG</jats:styled-content> anti‐<jats:styled-content style="fixed-case">HEV</jats:styled-content>–positive donations with viral loads of 250, 564, and 2755 <jats:styled-content style="fixed-case">IU</jats:styled-content>/<jats:styled-content style="fixed-case">mL</jats:styled-content>. The donation with highest viral load was genotype 3f. <jats:styled-content style="fixed-case">HEV RNA</jats:styled-content> positivity rate was one per 3333 donations (0.03%; 95% confidence interval, 0.01%‐0.09%).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>The <jats:styled-content style="fixed-case">P</jats:styled-content>rocleix <jats:styled-content style="fixed-case">HEV ID</jats:styled-content>‐<jats:styled-content style="fixed-case">NAT</jats:styled-content> screening system has provided evidence of <jats:styled-content style="fixed-case">HEV RNA</jats:styled-content> presence in <jats:styled-content style="fixed-case">C</jats:styled-content>atalan blood donors. Further data are needed to assess the impact of <jats:styled-content style="fixed-case">HEV</jats:styled-content> infection in at‐risk patients to design the best strategy to increase blood safety.</jats:p></jats:sec>

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: